comparemela.com
Home
Live Updates
Capsida Biotherapeutics Presents New Preclinical Evidence Indicating Novel First-in-Class IV-Administered Gene Therapy Effectively Treats Genetic Epilepsy Due to STXBP1 Mutations : comparemela.com
Capsida Biotherapeutics Presents New Preclinical Evidence Indicating Novel First-in-Class IV-Administered Gene Therapy Effectively Treats Genetic Epilepsy Due to STXBP1 Mutations
/PRNewswire/ -- Capsida Biotherapeutics ("Capsida") today announced new preclinical data supporting the potential of Capsida's gene therapy candidate, CAP-002,...
Related Keywords
,
Mingshan Xue ,
Capsida Biotherapeutics ,
Wu Chen ,
Susan Catalano ,
Human Genetics At Baylor College Of Medicine ,
Department Of Molecular ,
Capsida Program For Genetic Epilepsy Due ,
Baltimore Convention Center ,
Baylor College Of Medicine ,
Department Of Neuroscience ,
American Society Of Gene Cell Therapy ,
Cain Foundation Laboratories ,
Associate Professor ,
Human Genetics ,
Baylor College ,
Dan Duncan Neurological Research Institute ,
Texas Children ,
Therapy Corrects Neurological Phenotypes ,
Clinically Relevant Doses ,
Mouse Model ,
Related Developmental ,
Epileptic Encephalopathy ,
American Society ,
Cell Therapy ,
Neurologic Diseasesi Session ,
Next Generation Capsids ,
Chief Scientific Officer Susan Catalano ,
Genetic Epilepsy Due ,
comparemela.com © 2020. All Rights Reserved.